Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Theravance Biopharma Inc (NASDAQ: TBPH) closed the day trading at $17.61 down -1.12% from the previous closing price of $17.81. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 0.52 million shares were traded. TBPH stock price reached its highest trading level at $17.88 during the session, while it also had its lowest trading level at $17.25.
Ratios:
For a better understanding of TBPH, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.66. For the most recent quarter (mrq), Quick Ratio is recorded 9.48 and its Current Ratio is at 9.48. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on December 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $27.
On September 12, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $28.
Leerink Partners Downgraded its Outperform to Market Perform on August 06, 2024, whereas the target price for the stock was revised from $15 to $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Farnum Rhonda sold 31,067 shares for $18.75 per share. The transaction valued at 582,501 led to the insider holds 277,695 shares of the business.
RHONDA FARNUM bought 31,067 shares of TBPH for $582,500 on Dec 03 ’25. On Nov 26 ’25, another insider, ERAN BROSHY, who serves as the Director of the company, bought 29,501 shares for $20.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TBPH now has a Market Capitalization of 892341568 and an Enterprise Value of 607256512. As of this moment, Theravance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.31, and their Forward P/E ratio for the next fiscal year is 19.51. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.11 while its Price-to-Book (P/B) ratio in mrq is 3.84. Its current Enterprise Value per Revenue stands at 7.56 whereas that against EBITDA is -19.486.
Stock Price History:
The Beta on a monthly basis for TBPH is 0.14, which has changed by 0.8044579 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, TBPH has reached a high of $20.33, while it has fallen to a 52-week low of $7.90. The 50-Day Moving Average of the stock is 9.47%, while the 200-Day Moving Average is calculated to be 44.36%.
Shares Statistics:
Over the past 3-months, TBPH traded about 424.01K shares per day on average, while over the past 10 days, TBPH traded about 502410 shares per day. A total of 50.67M shares are outstanding, with a floating share count of 47.26M. Insiders hold about 6.73% of the company’s shares, while institutions hold 96.46% stake in the company. Shares short for TBPH as of 1764288000 were 5592921 with a Short Ratio of 13.19, compared to 1761868800 on 5082015. Therefore, it implies a Short% of Shares Outstanding of 5592921 and a Short% of Float of 17.729999.
Earnings Estimates
The market rating for Theravance Biopharma Inc (TBPH) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.76 and -$0.21 for the fiscal current year, implying an average EPS of $0.12. EPS for the following year is $1.69, with 3.0 analysts recommending between $3.85 and -$0.29.
Revenue Estimates
6 analysts predict $43M in revenue for. The current quarter. It ranges from a high estimate of $46.4M to a low estimate of $28M. As of. The current estimate, Theravance Biopharma Inc’s year-ago sales were $18.75MFor the next quarter, 6 analysts are estimating revenue of $23.84M. There is a high estimate of $47.4M for the next quarter, whereas the lowest estimate is $16.9M.
A total of 6 analysts have provided revenue estimates for TBPH’s current fiscal year. The highest revenue estimate was $108.6M, while the lowest revenue estimate was $107.19M, resulting in an average revenue estimate of $107.75M. In the same quarter a year ago, actual revenue was $64.38MBased on 6 analysts’ estimates, the company’s revenue will be $86.9M in the next fiscal year. The high estimate is $95.6M and the low estimate is $82M.
